Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites

Carlos Gomez-Roca, Christophe M. Raynaud, Frederique Penault-Llorca, Olaf Mercier, Frederic Commo, Luc Morat, Laure Sabatier, Philipe Dartevelle, Estelle Taranchon, Benjamin Besse, Pierre Validire, Antoine Italiano, Jean Charles Soria

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

INTRODUCTION: The use of biomarkers to evaluate the presence of a target or to select a specific therapy is increasingly advocated. The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC). METHODS: The expression of epidermal growth factor receptor (EGFR), excision repair cross-complementing (ERCC1), vascular-endothelial growth factor receptor, and Ki-67 was immunohistochemically analyzed in tumor samples of primary NSCLC and one corresponding metastasis in a population of 49 patients. RESULTS: Sixteen cases (33%) displayed clear discordance in the EGFR status between the primary tumor and the metastasis, with a significant trend toward downregulation of EGFR in the metastasis (p = 0.01). The ERCC1 status was discordant in 20 cases (41%), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively). The vascular-endothelial growth factor receptor and Ki-67 statuses were discordant in 13 (27%) and 15 (31%) cases, respectively. No difference in expression was observed between synchronous and metachronous metastasis. CONCLUSION: Biomarker expression is discordant between the primary tumor and its corresponding metastasis in about one third of patients with NSCLC. These findings should be considered in the setting of clinical trials and further explored using frozen material and high-throughput techniques.

Original languageEnglish
Pages (from-to)1212-1220
Number of pages9
JournalJournal of Thoracic Oncology
Volume4
Issue number10
DOIs
Publication statusPublished - 1 Oct 2009
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Biomarkers
Neoplasm Metastasis
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor Receptor
Neoplasms
DNA Repair
Down-Regulation
Clinical Trials
Brain
Population

Keywords

  • Biomarker
  • Corresponding metastasis
  • ERCC1
  • Non-small cell lung cancer
  • Primary tumor

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. / Gomez-Roca, Carlos; Raynaud, Christophe M.; Penault-Llorca, Frederique; Mercier, Olaf; Commo, Frederic; Morat, Luc; Sabatier, Laure; Dartevelle, Philipe; Taranchon, Estelle; Besse, Benjamin; Validire, Pierre; Italiano, Antoine; Soria, Jean Charles.

In: Journal of Thoracic Oncology, Vol. 4, No. 10, 01.10.2009, p. 1212-1220.

Research output: Contribution to journalArticle

Gomez-Roca, C, Raynaud, CM, Penault-Llorca, F, Mercier, O, Commo, F, Morat, L, Sabatier, L, Dartevelle, P, Taranchon, E, Besse, B, Validire, P, Italiano, A & Soria, JC 2009, 'Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites', Journal of Thoracic Oncology, vol. 4, no. 10, pp. 1212-1220. https://doi.org/10.1097/JTO.0b013e3181b44321
Gomez-Roca, Carlos ; Raynaud, Christophe M. ; Penault-Llorca, Frederique ; Mercier, Olaf ; Commo, Frederic ; Morat, Luc ; Sabatier, Laure ; Dartevelle, Philipe ; Taranchon, Estelle ; Besse, Benjamin ; Validire, Pierre ; Italiano, Antoine ; Soria, Jean Charles. / Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. In: Journal of Thoracic Oncology. 2009 ; Vol. 4, No. 10. pp. 1212-1220.
@article{d39fc5266e39490db6f9d7d71fb8a0c6,
title = "Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites",
abstract = "INTRODUCTION: The use of biomarkers to evaluate the presence of a target or to select a specific therapy is increasingly advocated. The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC). METHODS: The expression of epidermal growth factor receptor (EGFR), excision repair cross-complementing (ERCC1), vascular-endothelial growth factor receptor, and Ki-67 was immunohistochemically analyzed in tumor samples of primary NSCLC and one corresponding metastasis in a population of 49 patients. RESULTS: Sixteen cases (33{\%}) displayed clear discordance in the EGFR status between the primary tumor and the metastasis, with a significant trend toward downregulation of EGFR in the metastasis (p = 0.01). The ERCC1 status was discordant in 20 cases (41{\%}), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively). The vascular-endothelial growth factor receptor and Ki-67 statuses were discordant in 13 (27{\%}) and 15 (31{\%}) cases, respectively. No difference in expression was observed between synchronous and metachronous metastasis. CONCLUSION: Biomarker expression is discordant between the primary tumor and its corresponding metastasis in about one third of patients with NSCLC. These findings should be considered in the setting of clinical trials and further explored using frozen material and high-throughput techniques.",
keywords = "Biomarker, Corresponding metastasis, ERCC1, Non-small cell lung cancer, Primary tumor",
author = "Carlos Gomez-Roca and Raynaud, {Christophe M.} and Frederique Penault-Llorca and Olaf Mercier and Frederic Commo and Luc Morat and Laure Sabatier and Philipe Dartevelle and Estelle Taranchon and Benjamin Besse and Pierre Validire and Antoine Italiano and Soria, {Jean Charles}",
year = "2009",
month = "10",
day = "1",
doi = "10.1097/JTO.0b013e3181b44321",
language = "English",
volume = "4",
pages = "1212--1220",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "10",

}

TY - JOUR

T1 - Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites

AU - Gomez-Roca, Carlos

AU - Raynaud, Christophe M.

AU - Penault-Llorca, Frederique

AU - Mercier, Olaf

AU - Commo, Frederic

AU - Morat, Luc

AU - Sabatier, Laure

AU - Dartevelle, Philipe

AU - Taranchon, Estelle

AU - Besse, Benjamin

AU - Validire, Pierre

AU - Italiano, Antoine

AU - Soria, Jean Charles

PY - 2009/10/1

Y1 - 2009/10/1

N2 - INTRODUCTION: The use of biomarkers to evaluate the presence of a target or to select a specific therapy is increasingly advocated. The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC). METHODS: The expression of epidermal growth factor receptor (EGFR), excision repair cross-complementing (ERCC1), vascular-endothelial growth factor receptor, and Ki-67 was immunohistochemically analyzed in tumor samples of primary NSCLC and one corresponding metastasis in a population of 49 patients. RESULTS: Sixteen cases (33%) displayed clear discordance in the EGFR status between the primary tumor and the metastasis, with a significant trend toward downregulation of EGFR in the metastasis (p = 0.01). The ERCC1 status was discordant in 20 cases (41%), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively). The vascular-endothelial growth factor receptor and Ki-67 statuses were discordant in 13 (27%) and 15 (31%) cases, respectively. No difference in expression was observed between synchronous and metachronous metastasis. CONCLUSION: Biomarker expression is discordant between the primary tumor and its corresponding metastasis in about one third of patients with NSCLC. These findings should be considered in the setting of clinical trials and further explored using frozen material and high-throughput techniques.

AB - INTRODUCTION: The use of biomarkers to evaluate the presence of a target or to select a specific therapy is increasingly advocated. The correlation of biomarker expression between the primary tumor and its corresponding metastasis has not yet been well documented and analyzed in patients with non-small cell lung cancer (NSCLC). METHODS: The expression of epidermal growth factor receptor (EGFR), excision repair cross-complementing (ERCC1), vascular-endothelial growth factor receptor, and Ki-67 was immunohistochemically analyzed in tumor samples of primary NSCLC and one corresponding metastasis in a population of 49 patients. RESULTS: Sixteen cases (33%) displayed clear discordance in the EGFR status between the primary tumor and the metastasis, with a significant trend toward downregulation of EGFR in the metastasis (p = 0.01). The ERCC1 status was discordant in 20 cases (41%), with a trend toward overexpression in brain and adrenal metastases (p = 0.01 and p = 0.08, respectively). The vascular-endothelial growth factor receptor and Ki-67 statuses were discordant in 13 (27%) and 15 (31%) cases, respectively. No difference in expression was observed between synchronous and metachronous metastasis. CONCLUSION: Biomarker expression is discordant between the primary tumor and its corresponding metastasis in about one third of patients with NSCLC. These findings should be considered in the setting of clinical trials and further explored using frozen material and high-throughput techniques.

KW - Biomarker

KW - Corresponding metastasis

KW - ERCC1

KW - Non-small cell lung cancer

KW - Primary tumor

UR - http://www.scopus.com/inward/record.url?scp=70349706155&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349706155&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e3181b44321

DO - 10.1097/JTO.0b013e3181b44321

M3 - Article

C2 - 19687761

AN - SCOPUS:70349706155

VL - 4

SP - 1212

EP - 1220

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 10

ER -